Nuveen LLC Purchases New Holdings in CureVac N.V. $CVAC

Nuveen LLC purchased a new stake in shares of CureVac N.V. (NASDAQ:CVAC) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 83,219 shares of the company’s stock, valued at approximately $232,000.

Other large investors have also bought and sold shares of the company. Greenleaf Trust purchased a new stake in CureVac in the first quarter worth $31,000. Two Sigma Advisers LP purchased a new stake in CureVac in the fourth quarter worth $48,000. D. E. Shaw & Co. Inc. purchased a new stake in CureVac in the fourth quarter worth $66,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in CureVac by 14.3% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,125 shares of the company’s stock worth $81,000 after buying an additional 3,648 shares during the last quarter. Finally, Ballentine Partners LLC increased its position in CureVac by 81.8% in the first quarter. Ballentine Partners LLC now owns 31,573 shares of the company’s stock worth $88,000 after buying an additional 14,210 shares during the last quarter. 17.26% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. JMP Securities reissued a “market outperform” rating and issued a $10.00 target price on shares of CureVac in a research report on Wednesday, May 28th. Jefferies Financial Group reissued a “hold” rating and issued a $5.00 target price (down from $7.00) on shares of CureVac in a research report on Friday, June 13th. Citizens Jmp downgraded CureVac from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 12th. UBS Group lowered CureVac from a “strong-buy” rating to a “neutral” rating and cut their price target for the stock from $12.00 to $5.50 in a report on Thursday, June 26th. Finally, Citigroup lowered CureVac to a “market perform” rating in a report on Thursday, June 12th. One investment analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, CureVac presently has an average rating of “Hold” and a consensus target price of $6.83.

CureVac Price Performance

CureVac stock opened at $5.39 on Friday. CureVac N.V. has a one year low of $2.37 and a one year high of $5.72. The business has a fifty day moving average price of $5.43 and a 200-day moving average price of $4.28. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.17 and a quick ratio of 6.16. The firm has a market capitalization of $1.21 billion, a P/E ratio of 5.61 and a beta of 2.53.

CureVac (NASDAQ:CVAC) last posted its quarterly earnings results on Thursday, August 21st. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.15). The company had revenue of $1.41 million during the quarter, compared to the consensus estimate of $4.27 million. CureVac had a return on equity of 29.57% and a net margin of 38.21%. As a group, equities research analysts forecast that CureVac N.V. will post 0.72 EPS for the current year.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.